These drugs mimic the physiological effects of GLP-1 by binding to GLP-1R, which enhances insulin secretion, inhibits glucagon release, delays gastric emptying, and reduces food intake (Drucker, 2018)
declares having received honoraria from AstraZeneca, Bayer Yakuhin, Boehringer Ingelheim Japan, Daiichi Sankyo, Eli Lilly Japan, Kowa, Mitsubishi Tanabe Pharma, Mochida Pharmaceutical, MSD, Novartis Pharma, Novo Nordisk Pharma, Ono Pharmaceutical, Otsuka and Tsumura
Commonly used in GH axis research
Researchers should not treat them as substitutes for each other based solely on their shared appearance in tissue-repair literature
Researchers should consult both pharmacokinetic and pharmacodynamic data when interpreting results from any peptide half-life chart reference
Many report notable results within weeks of initiating semaglutide treatment